TY  - GEN
TI  - Tocilizumab
AU  - Venkiteshwaran, Adith
PY  - 2009
PB  - Landes Bioscience
LA  - eng
KW  - Mini Reviews
AB  - Roche is co-developing tocilizumab (Actemra, RoActemra), a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, with Chugai Pharmaceutical. Tocilizumab is marketed in Japan for Castleman disease and several types of arthritis. The product is approved in the European Union for treatment of moderate-to-severe rheumatoid arthritis, and is currently undergoing review by the US Food and Drug Administration for this condition. Tocilizumab has also been studied for potential use in the treatment of other IL-6 related disorders including Crohn disease.
UR  - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759492
UR  - https://www.pollux-fid.de/r/base-ftpubmed:oai:pubmedcentral.nih.gov:2759492
H1  - Pollux (Fachinformationsdienst Politikwissenschaft)
ER  -